Mark Lampert, Biotechnology Value Fund Up Stake In Cytokinetics, Inc. (CYTK), Reduce Exposure To Regado Biosciences Inc (RGDO)

Mark Lampert, the founder and manager of Biotechnology Value Fund, is bullish on Cytokinetics, Inc. (NASDAQ:CYTK). According to a recent filing with the Securities and Exchange Commission, Lampert has increased his fund’s stake from 1.79 million to 3.28 million shares, which include some 921,100 shares which can be issued upon the exercise of certain warrants. The fund’s current position accounts for 9.98% of the company’s common stock.

In another filing with the SEC, Biotechnology Value Fund has revealed a reduction in its holding of Regado Biosciences Inc (NASDAQ:RGDO) by 1.32 million shares that were disposed of, leaving the fund with 2.33 million shares which account for 9.99% of the company’s common stock.

Cytokinetics, Inc. (NASDAQ:CYTK)

Cytokinetics, Inc. (NASDAQ:CYTK) has also attracted the attention of Paul Ruddock and Steve Heinz, the managers of Lansdowne Partners. According to the fund’s latest 13F report, it holds 2.02 million shares valued at $13.1 million, the position suffering no changes in the previous quarter. Jim Simmons is also bullish on this stock, having initiated a position during the fourth quarter of 2013. Renaissance Technologies reported the ownership of 335,300 shares worth $2.17 million in its latest 13F filing. Israel Englander, the manager of Millennium Management, has decided to limit his exposure to Cytokinetics and has decreased his fund’s position by 36% to 554,700 shares valued at $3.6 million.

Cytokinetics, Inc. (NASDAQ:CYTK) engages in the research and design of small molecule therapeutics. The stock has a market cap of $326 million and does not pay a dividend. The stock has entered an uptrend at the end of 2013 and has advanced 38% so far this year to a current price of $8.95 per share. For the three months ending December 31, 2014, Cytokinetics posted revenues of $24.35 million and earnings per share of $0.22, up from a loss of $0.48 per share reported for the same period in 2012. Analysts expect the company to register $7.69 million in revenues and a loss per share of $0.35 during the current quarter.

Regado Biosciences Inc (NASDAQ:RGDO)

Only two hedge funds that we track have invested in Regado Biosciences Inc (NASDAQ:RGDO), one of them being Wexford Capital run by Charles Davidson. According to the fund’s latest 13F report, during the previous quarter, it has decreased its holding of the stock by 9% to 324,200 shares valued at $1.54 million. Alyeska Investment Group and its manager, Anand Parekh, are actually bullish and have increased their holding by 76% to 116,000 shares reportedly worth $553,000.

A developer of antithrombotic drug systems, Regado Biosciences Inc (NASDAQ:RGDO) has a market cap of $303 million and does not pay a dividend. The stock has been in an uptrend since the start of the year and has advanced 145% to a current price of $12 per share. For the year ending December 31, 2013, the company posted a net loss of $34.4 million, which translated into a loss per share of $4.59.

Disclosure: none.

Recommended reading:

CST Brands Inc (CST): Another Spin-Off Favored by Hedge Funds

Hedge Funds Go Crazy for Carter’s, Inc. (CRI)

Park West Asset Management Boosts Passive Stake In Move Inc. (MOVE)

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!